Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon alpha-2b - Beijing Kawin Technology

Drug Profile

Interferon alpha-2b - Beijing Kawin Technology

Alternative Names: Interferon alpha-2b vaginal effervescent tablet - Beijing Kawin technology; Recombinant human interferon alpha-2b injection - Beijing Kawin technology

Latest Information Update: 28 Aug 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Kawin Technology Share-Holding
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Basal cell cancer; Chronic myeloid leukaemia; Condylomata acuminata; Hairy cell leukaemia; Hepatitis B; Hepatitis C; Herpes zoster; Kaposi's sarcoma; Lymphoma; Malignant melanoma; Multiple myeloma; Ovarian cancer; Renal cancer; Uterine diseases

Most Recent Events

  • 17 Apr 2016 Biomarkers information updated
  • 27 Aug 2015 Launched for Basal cell cancer in China (Intratumoural) before August 2015
  • 27 Aug 2015 Launched for Chronic myeloid leukaemia in China (IM) before August 2015
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top